Dolutegravir plus rilpivirine as dual regimen in virologically suppressed HIV-1 infected patients in a clinical setting

Dolutegravir plus rilpivirine as dual regimen in virologically suppressed HIV-1 infected patients in a clinical setting

Objectives: There are scarce data on the combination of dolutegravir (DTG) plus rilpivirine (RPV) in the real world, including patients with hepatitis C virus (HCV) coinfection, toxicity or previous failure, or at risk for severe drug–drug interactions (DDIs). Methods: Prospective cohort study of vi...

Full description

Bibliographic Details
Main Authors: Jose L. Casado, Marta Monsalvo, María Fontecha, Pilar Vizcarra, Miguel A Rodriguez, María Jesús Vivancos, Santiago Moreno
Format: Article
Language:English
Published: Taylor & Francis Group 2019-04-01
Series:HIV Research & Clinical Practice
Subjects:
dual therapy
dolutegravir
rilpivirine
switching
simplification
Online Access:http://dx.doi.org/10.1080/15284336.2019.1628460

Internet

http://dx.doi.org/10.1080/15284336.2019.1628460

Similar Items